Vincent Pradel

Vincent Pradel

Auto-generated profile, based on publicly available information

Vincent Pradel

Assistance Publique des Hôpitaux de Marseille, France

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2003 in Leukemia
Verified
Journal Article
Open access
PDF file
JGJ Gabert
J Gabert
EBE Beillard
E Beillard
VVV H J van der Velden
V H J van der Velden
WBW Bi
W Bi
DGD Grimwade
D Grimwade
JDJacques J.M. van Dongen
Jacques J.M. van Dongen
Detection of minimal residual disease (MRD) has proven to provide independent prognostic information for treatment stratification in several types of leukemias such as childhood acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and acute promyelocytc leukemia. This report focuses on the accurate quantitative measurement of fusion gene (FG) transcripts as can be applied in 35–45% of ALL and acute myeloid leukemia, and in more than 90% of CML. A total of 26 European university laboratories from 10 countries have collaborated to establish a standardized protocol for TaqMan-based real-time quantitative PCR (RQ-PCR) analysis of the main leukemia-associated FGs within the Europe Against Cancer (EAC) program. Four phases were scheduled: (1) training, (2) optimization, (3) sensitivity testing and (4) patient sample testing. During our program, three quality control rounds on a large series of coded RNA samples were performed including a balanced randomized assay, which enabled final validation of the EAC primer and probe sets. The expression level of the nine major FG transcripts in a large series of stored diagnostic leukemia samples (n=278) was evaluated. After normalization, no statistically significant difference in expression level was observed between bone marrow and peripheral blood on paired samples at diagnosis. However, RQ-PCR revealed marked differences in FG expression between transcripts in leukemic samples at diagnosis that could account for differential assay sensitivity. The development of standardized protocols for RQ-PCR analysis of FG transcripts provides a milestone for molecular determination of MRD levels. This is likely to prove invaluable to the management of patients entered into multicenter therapeutic trials.

19 April 2006 in Human Psychopharmacology: Clinical and Experimental
Verified
Journal Article
Closed access
PDF file
NNN. Nguyen
N. Nguyen
EFE. Fakra
E. Fakra
VPV. Pradel
V. Pradel
EJElisabeth Jouve
Elisabeth Jouve
CAC. Alquier
C. Alquier
OBO. Blin
O. Blin

28 November 2008 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
VPVincent Pradel
Vincent Pradel
EFElisabeth Frauger
Elisabeth Frauger
XTXavier Thirion
Xavier Thirion
EREléonore Ronfle
Eléonore Ronfle
VLVéronique Lapierre
Véronique Lapierre
JMJoëlle Micallef
Joëlle Micallef

24 December 2001 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
XTX. Thirion
X. Thirion
VLV. Lapierre
V. Lapierre
JMJ. Micallef
J. Micallef
ERE. Ronflé
E. Ronflé
AMA. Masut
A. Masut
JSJ.L. Sanmarco
J.L. Sanmarco

1 July 2010 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
VPVincent Pradel
Vincent Pradel
CDCatherine Delga
Catherine Delga
FRFrank Rouby
Frank Rouby
JMJoëlle Micallef
Joëlle Micallef
MLMaryse Lapeyre-Mestre
Maryse Lapeyre-Mestre

15 September 2003 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
VPVincent Pradel
Vincent Pradel
XTXavier Thirion
Xavier Thirion
EREléonore Ronfle
Eléonore Ronfle
AMAlain Masut
Alain Masut
JMJoëlle Micallef
Joëlle Micallef
BBBernard Bégaud
Bernard Bégaud